Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Fenghuang Zhan to Multiple Myeloma

This is a "connection" page, showing publications Fenghuang Zhan has written about Multiple Myeloma.

 
Connection Strength
  
 
 
8.702
  
  1. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, Ashby C, Bauer MA, Hadidi SA, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024 11 06; 14(1):194.
    View in: PubMed
    Score: 0.389
  2. Guo W, Zhan Y, Mery D, Siegel ER, Sun F, Cheng Y, Ashby TC, Zhang Z, Bailey C, Alapat DV, Peng H, Hadidi SA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood Cancer J. 2024 02 14; 14(1):30.
    View in: PubMed
    Score: 0.370
  3. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615.
    View in: PubMed
    Score: 0.368
  4. Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2024 01 02; 134(1).
    View in: PubMed
    Score: 0.367
  5. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma. Cell Rep Med. 2023 10 17; 4(10):101214.
    View in: PubMed
    Score: 0.361
  6. Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 06 29; 16(1):70.
    View in: PubMed
    Score: 0.354
  7. Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest. 2022 09 15; 132(18).
    View in: PubMed
    Score: 0.335
  8. Li C, Xia J, Franqui-Machin R, Chen F, He Y, Ashby TC, Teng F, Xu H, Liu D, Gai D, Johnson SK, van Rhee F, Janz S, Shaughnessy JD, Tricot G, Frech I, Zhan F. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Invest. 2021 07 15; 131(14).
    View in: PubMed
    Score: 0.309
  9. Gao M, Bai H, Jethava Y, Wu Y, Zhu Y, Yang Y, Xia J, Cao H, Franqui-Machin R, Nadiminti K, Thomas GS, Salama ME, Altevogt P, Bishop G, Tomasson M, Janz S, Shi J, Chen L, Frech I, Tricot G, Zhan F. Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. J Natl Cancer Inst. 2020 05 01; 112(5):507-515.
    View in: PubMed
    Score: 0.285
  10. Franqui-Machin R, Hao M, Bai H, Gu Z, Zhan X, Habelhah H, Jethava Y, Qiu L, Frech I, Tricot G, Zhan F. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018 07 02; 128(7):2877-2893.
    View in: PubMed
    Score: 0.249
  11. Gu Z, Xia J, Xu H, Frech I, Tricot G, Zhan F. NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase. J Hematol Oncol. 2017 01 13; 10(1):17.
    View in: PubMed
    Score: 0.226
  12. Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma. Clin Cancer Res. 2015 Dec 15; 21(24):5532-42.
    View in: PubMed
    Score: 0.204
  13. Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015 Feb 01; 75(3):594-604.
    View in: PubMed
    Score: 0.197
  14. Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget. 2014 Dec 15; 5(23):11986-97.
    View in: PubMed
    Score: 0.196
  15. Gu Z, Zhou W, Huang J, Yang Y, Wendlandt E, Xu H, He X, Tricot G, Zhan F. Nek2 is a novel regulator of B cell development and immunological response. Biomed Res Int. 2014; 2014:621082.
    View in: PubMed
    Score: 0.195
  16. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G, Zhan F. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013 Jan 14; 23(1):48-62.
    View in: PubMed
    Score: 0.172
  17. Wu X, Shi J, Wu Y, Tao Y, Hou J, Meng X, Hu X, Han Y, Jiang W, Tang S, Zangari M, Tricot G, Zhan F. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol Ther. 2010 Dec 01; 10(11):1201-14.
    View in: PubMed
    Score: 0.148
  18. Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD, Zhan F. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 2010 Jan 07; 115(1):61-70.
    View in: PubMed
    Score: 0.137
  19. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008 Jan 15; 111(2):968-9.
    View in: PubMed
    Score: 0.121
  20. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007 Feb 15; 109(4):1692-700.
    View in: PubMed
    Score: 0.111
  21. Qin L, Moreno Rueda LY, Ray U, Mahmud I, Tan L, Lorenzi PL, Liu S, Lin H, Mery DE, Zhan F, Shaughnessy JD, Yi Q, Acevedo Calado MJ, Wang H, Manasanch EE, Lee HC, Patel KK, Kuiatse I, Symer DE, Orlowski RZ. Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma. Blood. 2025 May 29; 145(22):2614-2629.
    View in: PubMed
    Score: 0.101
  22. Moreno Rueda LY, Wang H, Akagi K, Dang M, Vora A, Qin L, Lee HC, Patel KK, Lin P, Mery DE, Zhan F, Shaughnessy JD, Yi Q, Song Y, Jiang B, Gillison ML, Thomas SK, Weber DM, Diao L, Wang J, Kuiatse I, Manasanch EE, Symer DE, Orlowski RZ. Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets. Cell Rep Med. 2025 Feb 18; 6(2):101925.
    View in: PubMed
    Score: 0.099
  23. Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Zangari M, Barlogie B, van Rhee F. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2024 Nov; 99(11):2222-2224.
    View in: PubMed
    Score: 0.096
  24. Mao X, Yan W, Mery D, Liu J, Fan H, Xu J, Xu Y, Sui W, Deng S, Zou D, Du C, Yi S, van Rhee F, Barlogie B, Shaughnessy JD, Anderson KC, Zhan F, Qiu L, An G. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. Am J Hematol. 2024 04; 99(4):523-533.
    View in: PubMed
    Score: 0.092
  25. Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023 Jul 11; 7(13):3069-3074.
    View in: PubMed
    Score: 0.089
  26. Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 08 15; 129(16):2491-2498.
    View in: PubMed
    Score: 0.088
  27. Bloedjes TA, de Wilde G, Khan GH, Ashby TC, Shaughnessy JD, Zhan F, Houtkooper RH, Bende RJ, van Noesel CJM, Spaargaren M, Guikema JEJ. AKT supports the metabolic fitness of multiple myeloma cells by?restricting FOXO activity. Blood Adv. 2023 05 09; 7(9):1697-1712.
    View in: PubMed
    Score: 0.088
  28. Xu L, Wang Y, Wang G, Guo S, Yu D, Feng Q, Hu K, Chen G, Li B, Xu Z, Jia X, Lu Y, Zhang H, Gao X, Chang S, Wang H, Wu X, Song D, Yang G, Zhu H, Zhou J, Zhan F, Zhu W, Shi J. Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma. Leukemia. 2023 07; 37(7):1576-1579.
    View in: PubMed
    Score: 0.088
  29. Roy Choudhury S, Byrum SD, Alkam D, Ashby C, Zhan F, Tackett AJ, Van Rhee F. Expression of integrin ?-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics. Clin Epigenetics. 2023 02 04; 15(1):18.
    View in: PubMed
    Score: 0.086
  30. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood. 2003 Feb 01; 101(3):1128-40.
    View in: PubMed
    Score: 0.084
  31. Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877.
    View in: PubMed
    Score: 0.083
  32. Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, Pisano M, Zhan F, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Hari P, Janz S. FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene. 2022 08; 41(32):3899-3911.
    View in: PubMed
    Score: 0.083
  33. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002 Mar 01; 99(5):1745-57.
    View in: PubMed
    Score: 0.081
  34. Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo M, Wei R, Wang Y, Jurczyszyn A, Janz S, Beksac M, Zhan F, Seckinger A, Hose D, Pan J, Yang Y. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Mol Cancer. 2021 06 05; 20(1):84.
    View in: PubMed
    Score: 0.077
  35. Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front Immunol. 2021; 12:667054.
    View in: PubMed
    Score: 0.077
  36. Schinke CD, Bird JT, Qu P, Yaccoby S, Lyzogubov VV, Shelton R, Ling W, Boyle EM, Deshpande S, Byrum SD, Washam C, Mackintosh S, Stephens O, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Barlogie B, van Rhee F, Walker BA. PHF19 inhibition as a therapeutic target in multiple myeloma. Curr Res Transl Med. 2021 07; 69(3):103290.
    View in: PubMed
    Score: 0.076
  37. Jiang F, Tang X, Tang C, Hua Z, Ke M, Wang C, Zhao J, Gao S, Jurczyszyn A, Janz S, Beksac M, Zhan F, Gu C, Yang Y. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. J Hematol Oncol. 2021 04 01; 14(1):54.
    View in: PubMed
    Score: 0.076
  38. Deshpande S, Tytarenko RG, Wang Y, Boyle EM, Ashby C, Schinke CD, Thanendrarajan S, Zangari M, Zhan F, Davies FE, Morgan GJ, van Rhee F, Walker BA. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. Eur J Haematol. 2021 Feb; 106(2):230-240.
    View in: PubMed
    Score: 0.074
  39. Li Z, Liu L, Du C, Yu Z, Yang Y, Xu J, Wei X, Zhan F, Lai Y, Qiu L, Hao M. Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma. Cancer Gene Ther. 2020 12; 27(12):869-877.
    View in: PubMed
    Score: 0.070
  40. Wu C, Zhang L, Brockman QR, Zhan F, Chen L. Chimeric antigen receptor T cell therapies for multiple myeloma. J Hematol Oncol. 2019 11 21; 12(1):120.
    View in: PubMed
    Score: 0.069
  41. Tong J, Xu X, Zhang Z, Ma C, Xiang R, Liu J, Xu W, Wu C, Li J, Zhan F, Wu Y, Yan H. Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy. Haematologica. 2020 06; 105(6):1630-1640.
    View in: PubMed
    Score: 0.067
  42. Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S. Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. Haematologica. 2020 03; 105(3):e111-e115.
    View in: PubMed
    Score: 0.067
  43. Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer. 2018 Nov 21; 18(1):1152.
    View in: PubMed
    Score: 0.064
  44. Tomasson MH, Ali M, De Oliveira V, Xiao Q, Jethava Y, Zhan F, Fitzsimmons AM, Bates ML. Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. Int J Mol Sci. 2018 Nov 16; 19(11).
    View in: PubMed
    Score: 0.064
  45. Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S. Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer J. 2018 02 15; 8(2):22.
    View in: PubMed
    Score: 0.061
  46. Tao Y, Yang G, Yang H, Song D, Hu L, Xie B, Wang H, Gao L, Gao M, Xu H, Xu Z, Wu X, Zhang Y, Zhu W, Zhan F, Shi J. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget. 2017 Apr 18; 8(16):26718-26731.
    View in: PubMed
    Score: 0.058
  47. Xia J, Xu H, Zhang X, Allamargot C, Coleman KL, Nessler R, Frech I, Tricot G, Zhan F. Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. EBioMedicine. 2017 Apr; 18:41-49.
    View in: PubMed
    Score: 0.057
  48. Schibler J, Tomanek-Chalkley AM, Reedy JL, Zhan F, Spitz DR, Schultz MK, Goel A. Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells. PLoS One. 2016; 11(11):e0167323.
    View in: PubMed
    Score: 0.056
  49. Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget. 2015 Dec 01; 6(38):40496-506.
    View in: PubMed
    Score: 0.052
  50. Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015 Dec 01; 6(38):41275-89.
    View in: PubMed
    Score: 0.052
  51. Yang G, Gao M, Zhang Y, Kong Y, Gao L, Tao Y, Han Y, Wu H, Meng X, Xu H, Zhan F, Wu X, Shi J. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget. 2015 Sep 29; 6(29):26982-94.
    View in: PubMed
    Score: 0.052
  52. Gao L, Zhan F, Shi J. [Myeloma cancer stem cells:the new target for multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2014 Dec; 35(12):1134-7.
    View in: PubMed
    Score: 0.049
  53. Salem K, McCormick ML, Wendlandt E, Zhan F, Goel A. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biol. 2015; 4:23-33.
    View in: PubMed
    Score: 0.049
  54. Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, Zhan F, Qiu L. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015 Apr 15; 136(8):1835-44.
    View in: PubMed
    Score: 0.048
  55. Salama ME, Du S, Efimova O, Heikal NM, Wendlandt E, Toydemir RM, South S, Perkins SL, Hussong JW, Zhan F. Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities. Leuk Lymphoma. 2015 Feb; 56(2):426-33.
    View in: PubMed
    Score: 0.048
  56. Gao M, Gao L, Yang G, Tao Y, Hou J, Xu H, Hu X, Han Y, Zhang Q, Zhan F, Wu X, Shi J. Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism. Acta Biochim Biophys Sin (Shanghai). 2014 Jul; 46(7):597-604.
    View in: PubMed
    Score: 0.047
  57. Gao M, Gao L, Yang G, Tao Y, Tompkins VS, Wu X, Xu H, Zhan F, Shi J. Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials. Int J Clin Exp Pathol. 2014; 7(6):3073-80.
    View in: PubMed
    Score: 0.047
  58. An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014 Feb; 99(2):353-9.
    View in: PubMed
    Score: 0.045
  59. Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. PLoS One. 2013; 8(10):e77608.
    View in: PubMed
    Score: 0.045
  60. Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, Zhou W, Zhou Y, Das S, Gu Z, Levasseur D, Zhan F, Tricot G. RARa2 expression confers myeloma stem cell features. Blood. 2013 Aug 22; 122(8):1437-47.
    View in: PubMed
    Score: 0.044
  61. Veitonm?ki N, Hansson M, Zhan F, Sundberg A, L?fstedt T, Ljungars A, Li ZC, Martinsson-Niskanen T, Zeng M, Yang Y, Danielsson L, Kovacek M, Lundqvist A, M?rtensson L, Teige I, Tricot G, Frend?us B. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15; 23(4):502-15.
    View in: PubMed
    Score: 0.044
  62. Zangari M, Berno T, Zhan F, Tricot G, Fink L. Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Semin Thromb Hemost. 2012 Nov; 38(8):768-79.
    View in: PubMed
    Score: 0.042
  63. Zangari M, Terpos E, Zhan F, Tricot G. Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev. 2012 Dec; 38(8):968-80.
    View in: PubMed
    Score: 0.040
  64. Wu X, Shao Y, Tao Y, Ai G, Wei R, Meng X, Hou J, Han Y, Zhan F, Zheng J, Shi J. Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I. Biochem Biophys Res Commun. 2011 Nov 11; 415(1):187-92.
    View in: PubMed
    Score: 0.039
  65. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7.
    View in: PubMed
    Score: 0.038
  66. Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 2011 Feb; 96(2):333-6.
    View in: PubMed
    Score: 0.037
  67. Heerema-McKenney A, Waldron J, Hughes S, Zhan F, Sawyer J, Barlogie B, Shaughnessy JD. Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma. Am J Clin Pathol. 2010 Feb; 133(2):265-70.
    View in: PubMed
    Score: 0.035
  68. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010 Jan 01; 28(1):132-5.
    View in: PubMed
    Score: 0.034
  69. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD, Barlogie B, Yaccoby S, Afar DE. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep; 8(9):2616-24.
    View in: PubMed
    Score: 0.034
  70. Brenne AT, Fagerli UM, Shaughnessy JD, V?tsveen TK, R? TB, Hella H, Zhan F, Barlogie B, Sundan A, B?rset M, Waage A. High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis. Eur J Haematol. 2009 May; 82(5):354-63.
    View in: PubMed
    Score: 0.033
  71. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008 May 01; 14(9):2775-84.
    View in: PubMed
    Score: 0.031
  72. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, Thuro B, Melenhorst J, Barrett J, Shaughnessy J, Old LJ, Barlogie B, Brichard VG, van Rhee F. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother. 2007 Nov-Dec; 30(8):847-54.
    View in: PubMed
    Score: 0.030
  73. Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol. 2007 Sep; 138(6):802-11.
    View in: PubMed
    Score: 0.030
  74. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007 Aug; 12(2):115-30.
    View in: PubMed
    Score: 0.029
  75. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD, Sawyer J, Li JP, Zcharia E, Vlodavsky I, Sanderson RD. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem. 2007 May 04; 282(18):13326-33.
    View in: PubMed
    Score: 0.029
  76. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007 Mar 15; 109(6):2276-84.
    View in: PubMed
    Score: 0.028
  77. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006 Sep 01; 108(5):1724-32.
    View in: PubMed
    Score: 0.027
  78. Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J, Yaccoby S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol. 2006 Apr; 133(1):83-92.
    View in: PubMed
    Score: 0.027
  79. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Brennan C, Depinho RA. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006 Apr; 9(4):313-25.
    View in: PubMed
    Score: 0.027
  80. Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I, Huang Y, Ogura T, Takahashi S, Ueda R, Barlogie B, Shaughnessy J, Esumi H. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene. 2005 Oct 20; 24(46):6936-44.
    View in: PubMed
    Score: 0.026
  81. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005 Jul 01; 106(1):296-303.
    View in: PubMed
    Score: 0.025
  82. Shaughnessy J, Zhan F, Barlogie B, Stewart AK. Gene expression profiling and multiple myeloma. Best Pract Res Clin Haematol. 2005; 18(4):537-52.
    View in: PubMed
    Score: 0.025
  83. Lin P, Mahdavy M, Zhan F, Zhang HZ, Katz RL, Shaughnessy JD. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol. 2004 Oct; 17(10):1217-22.
    View in: PubMed
    Score: 0.024
  84. Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM, Barlogie B, Shaughnessy J, Reiman T. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood. 2004 Aug 15; 104(4):1151-8.
    View in: PubMed
    Score: 0.023
  85. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003 Dec 25; 349(26):2483-94.
    View in: PubMed
    Score: 0.023
  86. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 2003 Dec 15; 63(24):8749-56.
    View in: PubMed
    Score: 0.023
  87. Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R, Smit JW, Zhan F, Shaughnessy J, Bos NA. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol. 2003 Apr; 121(1):36-43.
    View in: PubMed
    Score: 0.022
  88. Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 2014 Aug; 59(1-3):188-202.
    View in: PubMed
    Score: 0.012
  89. Zangari M, Zhan F, Tricot G. Bone and paraproteinemias. Curr Opin Support Palliat Care. 2010 Sep; 4(3):195-9.
    View in: PubMed
    Score: 0.009
  90. Park ES, Shaughnessy JD, Gupta S, Wang H, Lee JS, Woo HG, Zhan F, Owens JD, Potter M, Janz S, Mushinski JF. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics. 2007 Aug 31; 8:302.
    View in: PubMed
    Score: 0.007
  91. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, R?me T, Legouffe E, Rossi JF, Shaughnessy J, ?rntoft TF, Klein B. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 2002 Aug 15; 100(4):1113-22.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.